Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN)
in
STATEMENT OF TRANSLATIONAL RELEVANCE:
The optimal therapeutic index for any given drug is a function of efficacy as well as toxicity. While much work has focused on the identification of biomarkers that predict efficacy, the discovery of high quality biomarkers that predict toxicity are lacking. Inherited genetic variation is one important source for the heterogeneity in toxicity seen across a population. Drug-induced side effects can create unnecessary, serious medical morbidity and can impact the global quality of life experience for the patient. A significant toxicity can also limit the full-intended receipt of a potentially life-saving therapy.
Taxane induced peripheral neuropathy is one of the most common and important toxicities across multiple disease types and settings. Herein we demonstrate that African American Race and a genetic variant (rs3125923) are important predictors for this toxicity.
Research. 
ABSTRACT Purpose
Taxane induced peripheral neuropathy (TIPN) is an important survivorship issue for many cancer patients. Currently, there are no clinically implemented biomarkers to predict which patients might be at increased risk for TIPN. We present a comprehensive approach to identification of genetic variants to predict TIPN.
Experimental Design
We performed a genome wide association study (GWAS) in 3431 patients from the phase III adjuvant breast cancer trial, ECOG-5103 to compare genotypes with TIPN. We performed candidate validation of top SNPs for TIPN in another phase III adjuvant breast cancer trial, ECOG-1199.
Results
When evaluating for Grade 3-4 TIPN, 120 SNPs had a p-value <10 -4 from patients of European descent (EA) in ECOG-5103. 30 candidate SNPs were subsequently tested in ECOG-1199 and SNP rs3125923 was found to be significantly associated with Grade 3-4 TIPN (p=1.7x10 ).
Conclusion
INTRODUCTION:
The taxanes are commonly used to treat patients with a variety of malignancies.(1, 2) While having improved outcomes, taxanes are not without toxicity. One of the most common toxicities is taxaneinduced peripheral neuropathy (TIPN). TIPN can substantially impact quality of life, can be irreversible, and limit drug exposure; occasionally requiring cessation of treatment. The likelihood of TIPN depends on the type of taxane used, dose, and schedule.(3) However, there is also substantial inter-individual heterogeneity and it is difficult to predict which patients will be at greatest risk for TIPN prior to receipt. 
METHODS:
Genome wide association study (GWAS) for SNP discovery in ECOG-5103 ECOG-5103 ( Figure 1A ) was a phase III adjuvant breast cancer trial that randomized 4994 patients with node positive or high-risk node negative breast cancer to intravenous doxorubicin and cyclophosphamide every 2 or 3 weeks (at discretion of treating physician) for four cycles (AC) followed by 12 weeks of weekly paclitaxel (P; 80 mg/m 2 ) alone (Arm A) or to the same chemotherapy with either concurrent bevacizumab (Arm B) or concurrent plus sequential bevacizumab (Arm C).(13) Germline (blood) DNA was available from 4033 patients. Genome-wide analyses were performed across all Arms to identify genotypes at single-nucleotide polymorphisms (SNPs) that were associated with TIPN.
ECOG-5103 case/control definitions for TIPN
Cases: Cases were defined as those experiencing Grade 2-4 TIPN (n=576 EA, 151AA) as assessed by the Common Toxicity Criteria Adverse Events (CTCAE) version 3.0. We separately assessed for those with the more extreme phenotype of Grade 3-4 (n=181 EA). Cases included patients who received at least one dose of paclitaxel and the neuropathy event occurred during treatment or within 3 months of the last dose of therapy.
Controls: Controls (n=781EA, 62AA) included patients who met all the following: 1). Received all planned doses of paclitaxel; 2). Had follow-up for at least 3 months after the last dose of drug; 3). Did not meet any of the case definitions as outlined above; and 4). Had either paclitaxel or bevacizumab held or modified for any reason (i.e. disease progression or other toxicity) were excluded.
Genotyping and Statistical analysis
Genotyping was performed in two distinct study subsets as described previously. (15) Genotyping array data was obtained on Illumina products and extensive quality review was performed to assure SNP quality, develop principal components for race assignment and imputation (see Supplemental Methods). Analyses were performed in genetically defined EA and AA subsets of the E5103 samples. Figure 1) , age, body surface area (BSA), Arm of study, menopausal status, and ER/PR status were considered as potential covariates. The threshold was set at p < 0.05 for inclusion of a covariate in the logistic regression model. PC1, age and BSA were significant predictors and were used in subsequent association analyses. The individual SNP effect is reported as odds ratio (OR) and p-value. SNPs available on the HumanOmni1-Quad array were included in the statistical analysis. An additive model of SNP effect was used and the analysis was performed using SNPTEST v2.4.(16) To correct for multiple SNP comparisons, the p-value threshold for genome wide significance was set at 5×10 -8 . ( 
RESULTS:

Rates of TIPN and clinical predictors
ECOG-5103
For the parent trial, depending on treatment arm 26-28% and 8-9% experienced TIPN of CTCAE v3.0
Grade 2-4 and 3-4 severity, respectively.(13) For the subset of 3169 patients who had analyzable genetic data, the risk of Grade 2-4 and Grade 3-4 TIPN was 27.6 % and 9.6 % respectively. Older age was a significant risk factor with a 13% increased risk per decade of life (p=9.3×10 -4 ). Increased BSA was also significantly associated with an increased risk of neuropathy (HR=2.8; p=7.1×10 -11 ). Race was genetically determined and those of African descent were markedly more likely to experience Grade 2-4 (HR=2.1; p=5.6×10 -16 ) and Grade 3-4 (HR=2.6; p=1.1×10 -11 ) TIPN compared to other races (Figure 2 ). This remained significant for both Grade 2-4 (p=5.6 x10 -14 ) and Grade 3-4 TIPN (p=1.4x10 -11 ) when correcting for both age and BSA. Additionally, the degree of PC1 after correction for age and BSA was even more significantly associated with Grade 2-4 (HR=0.5; p=9.4x10 -15 ) and Grade 3-4 (HR=0.37; p=7.4x10 -13 ) TIPN.
ECOG-1199
For the parent trial, depending on treatment arm 16-27% and 4-8% experienced TIPN of CTC v2.0 data, the risk of Grade 2-4 and Grade 3-4 TIPN was 19.8% and 6.2% respectively. For the parent trial, race was determined by self-report and was not associated with risk of TIPN for the entire cohort but there was a strong trend for increased risk in the weekly paclitaxel arm with a similar odds ratio to that seen in ECOG-5103.(18) Age was not significant but was considered as a covariate to maintain consistency across trials. Increased BSA (OR=1.9; p=0.0062) was significantly associated with an increased risk of neuropathy.
GWAS results for TIPN in EA subset from ECOG-5103
The strength of association between genotype and Grade 3-4 TIPN (Figure 3) and Grade 2-4 TIPN are demonstrated in Supplementary Table 2 and Supplementary Table 3 , respectively. 120 and 65 SNPs had a p-value <1x10 -4 for the Grade 3-4 analysis and the Grade 2-4 analysis, respectively.
Evaluation of top EA SNPs in ECOG-1199
30 SNPs were evaluated in ECOG-1199 based on p-value and LD support (Supplementary Table 4 ).
One SNP, rs3125923, was statistically significantly associated with increased risk of TIPN for Grade 3-4 severity after correction of multiple comparisons (p=1.7x10 
GWAS results for TIPN in AA subset from ECOG-5103
Given the marked increased risk of TIPN among the AA subset, we performed an exploratory analysis for AA patients for Grade 2-4 TIPN (insufficient cases for Grade 3-4). The strength of association between genotype and TIPN are shown in Figure 3 and Supplementary ; OR= 5.5).
DISCUSSION:
TIPN is considered one of the most important survivorship concerns for cancer patients. . In our validation study from ECOG-1199, 58.8% of SNPs genotyped had an acceptable call rate ≥ 95% which is similar to previously reported data on FFPE samples. (21) We identified a SNP, rs3125923, that was associated with a statistically significant increased risk for TIPN. rs3125923 is a variant in a gene desert on chromosome 1 and had LD support in our analysis (Supplementary Figure   2) . While understanding the functional implications of predictive SNPs is important, more than 80% of prior GWAS identified trait loci are in the non-coding regions of the genome, (22) harmonize some of these confounding variables may be a reasonable expectation based on the underlying biology and pharmacology. For example, while the host tissue may broadly predispose a patient to a given drug or drug class that can cause neuropathy, there are biological and pharmacokinetic differences, that may make the identification of a universal predictive biomarker impossible to identify.
The need to correct for all confounders, however, makes it difficult to use the marker in practice and begs the question as to which may be most valuable; a marker that is accurate for a very specific situation or a more generalizable marker with less statistical power. Regardless, novel genetic findings have the potential to unravel the underlying cause and potentially provide insight leading to novel drugs to prevent or treat TIPN. While our top SNP increased the risk, others with more modest associations decreased the risk. This speaks to the potential genetic complexity of predisposition for TIPN and also explains what is seen clinically, with some patients experiencing early and severe neuropathy while others never experience neuropathy. Multi-genetic models will ultimately need to be developed but will require multiple massive data sets for operative statistical power. Given the discordance in the data, it is highly likely that the most efficient and statistically well-poised approach will include a meta-analysis across several of these large datasets. Also, use of more high-throughput technology, such as massively parallel sequencing might further shed light on the genetic contributions. (9) The strengths of the current study include the non-biased evaluation of common variants across the genome in a discovery cohort from a large, adjuvant randomized phase III trial with attempted validation in a similarly sized and designed trial. Despite the lack of established functionality of the SNPs 
limitation was minimized by careful quality review of the genotypes including filtering of SNPs that did not meet stringent criteria for the rate of genotype calls, expected MAF, and deviation from HWE.
Additionally, none of these sites represent areas of frequent LOH nor somatic mutations in breast cancer. (27) Thus, while isolated cases of LOH or mutations cannot be ruled out at the individual level, at the trial level this did not appear to be an issue. Although race and obesity were significant independent predictors of peripheral neuropathy, other potentially important variables such as Diabetes Mellitus could also play a role. Unfortunately comorbidities and co-medications were not formally collected in either ECOG-5103 or ECOG-1199 and the inability to include them in modeling is a limitation to this study. Another limitation is the use of CTCAE phenotype definitions. Recent work has demonstrated patient reported outcomes (PROs) might be more sensitive. (28) The use of PROs in large trials is beginning to be used to help enhance clinically relevant interpretation and is destined to augment correlative studies such as these. Finally, although ECOG-5103 and ECOG-1199 were similar in design and size, there were some important differences. Important to this correlative work was the variability in taxane implemented and schedule. SNPs that might be docetaxel-specific would not have been identified from the discovery cohort that included only paclitaxel. Further, confirmation of paclitaxel-specific SNPs may have been underpowered in the validation cohort where only half the patients received paclitaxel. As we set out on this project, however, our hope was to identify a marker(s) that would predispose to neuropathy from the taxanes broadly.
In the group genome-wide genotyped from ECOG-5103, there was also a substantial increase in the risk for TIPN in AA patients. Further, the degree of African American ancestry (determined by PC1; with higher values representing less African ancestry) was even more statistically significant than the binary analysis. For example, the hazard ratio of 0.5 seen in the Grade 2-4 analysis meant that a 1-unit change in PC1 (reflecting a decrease in African ancestry) reduced the neuropathy risk by 50%. This analysis further supports that this is a true genetic effect, rather than environmental. Based on these data, AA patients should also be counseled about the increased risk of TIPN. As previously described, selfdefined race is often inaccurate and thus ECOG-5103 includes a truly unique cohort of genetically defined AA patients from a trial with rigorous uniformity for phenotype collection. The GWAS confined to AA patients did identify an interesting group of SNPs that associated with TIPN on Chromosome 1, including rs1856746. This SNP, found at 1q32. Although intriguing, this finding should only be regarded as hypothesis generating. Because of the substantial risk for TIPN in the AA cohort, additional work from other large data sets is warranted to confirm or refute these findings.
As markers of other toxicities from competing regimens emerge, more personalized treatment regimens can be recommended. The ultimate goal, however, is to identify therapies that might treat or prevent these toxicities. The genetic findings for predisposition might serve nicely to help unravel the mechanistic underpinnings, an important first step in therapeutic development and improved patient care.
Research. Research. Table 2 . Selected SNPs previously reported to be associated with taxane-induced peripheral neuropathy ). The number of patients that had follow-up data and were still at risk for neuropathy at each time point is displayed below.
(B) The frequency of G3-4 peripheral neuropathy in the genotyped cohort was 18.4% for those of African descent vs. 8.1% for all other races combined (p-value=1.1 x 10 -11 ). The number of patients that had follow up data and were still at risk for neuropathy at each time point is displayed below. 
